"Take a Closer Look", page-293

Suckii's HSV2 Final Results

Sci9249 - A discussion on HSV2 results and what to expect and are we compared against the
Genocea results?
Bottle2 - To prove platform technology and add a lot of financial value going forward- a shot in the dark.
ThatsOldMate - Hoping/Expecting and to prove that the HSV2 vax has found the hiding spots of the virus/Reputation at stake.
Unstable- Keep it real, long shot.
Sunnycoast - (inflection point) transform the health sectors.

A discussion on HSV2 results, you bet. I would like to start at the beginning of HSV2 for this was not a long shot, or hoping and expecting to find the hiding spots of the virus, or was it a shot in the dark? These are the questions I have selected to try and answer.
I personally believe that the most important part of the HSV2 trial is the T cell activation, this is what immunotherapy is trying to achieve, which will show that Professor Ian Frazer theory works.
But what does this mean?
It means that the proteins that the Professor is using patented to ADMEDUS, let me elaborate for you, the proteins are the extra boost to the vax, I think they are the E6 and E7 proteins. It is the proteins that open up the hiding spots of the virus to allow the vax to work at 100% or nerve endings. (Hiding spot)
So are we going to be compared to Genocea results? I believe that Genocea results are the best so far but the scientific world and Genocea can already see that ADMEDUS has absolutely smashed all competition in this space with no comparison. Even Genocea will try to boost their vax by asking Professor Frazer to try and mix the right proteins to boost their vax or have a very big tax loss. But what does all this mean?
It means that the vax is not only the best in the market going forward to phase 3 but it also proves the platform technology works. I have explained this in a previous post which in turn puts a value on the IP (Intellectual Property) which is about 73% of the IP which belongs to ADMEDUS and if you think that it is not worth a lot of money have a closer look.
Genocea has spent a lot of money to get to HSV2, let's say US $ 500,000,000 and if you think that I have overshot the number let me say that other companies that didn't get good results and terminated after HSV2 results put in a tax loss of 2 billion dollars. So I don't think that my numbers are over done, under maybe. So when the results come out it will be the start of inflection point to transform the health sectors. So what I am saying is that ADMEDUS is worth a lot more than what has been stated by any organisation or research professionals.
(Reputation are at stake)

References: 2017 Immunotherapies (Breakthrough)

* The video of Professor Ian Frazer doing a Tom Cruise. This was the video that HC pulled. Profesor Frazer knows that the T cell response was a breakthrough and without the results (proof) under company law this video had to be pulled.
* And WP explaining after 25 years in big Pharma and 30 products launched, this would be the time to get excited.

PS: Now if you are looking for a comet or the X Factor you better start looking up.